Review Article
How to optimize HCV therapy in genotype 4 patients
Article first published online: 3 JAN 2013
DOI: 10.1111/liv.12059
© 2012 John Wiley & Sons A/S
Issue

Liver International
Special Issue: Proceedings of the 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis
Volume 33, Issue Supplement s1, pages 41–45, February 2013
Additional Information
How to Cite
Esmat, G., El Kassas, M., Hassany, M., Gamil, M. E. and El Raziky, M. (2013), How to optimize HCV therapy in genotype 4 patients. Liver International, 33: 41–45. doi: 10.1111/liv.12059
Publication History
- Issue published online: 3 JAN 2013
- Article first published online: 3 JAN 2013
- Abstract
- Article
- References
- Cited By
Keywords:
- genotype 4;
- hepatitis C virus;
- treatment predictors
Abstract
HCV is a worldwide disease with an estimated prevalence by WHO of 3%. Hepatitis C virus 4 is prevalent in Africa and the Middle East, especially Egypt. The treatment of HCV4 is affected by many factors, related to the virus itself (genotype, pretreatment viral load and prevalent quasispecies), to the host (genetic factors, age, ethnicity and liver histology), to the presence of comorbidities (obesity, insulin resistance and co-infections) and to the therapeutic drugs (type, dose and duration). Optimizing treatment is the goal of daily practice to obtain the best results for the patient.

1478-3231/asset/LIV_left.gif?v=1&s=85fae709761c931e1b1f055c02ebb481958f0f73)